IDM Pharma Announces Upcoming Clinical Data Presentations

IDM Pharma, Inc. (Nasdaq: IDMI), a biotechnology company focused on the development of innovative cancer therapies, announced details on clinical data presentations evaluating three of the Company’s pipeline compounds to be presented at upcoming medical congresses. Specific presentation details are as follows: Mifamurtide (L-MTP-PE): Connective Tissue Oncology Society (CTOS) — Seattle, Wash. [click link for full article]

More: continued here

Filed under: Cancer on October 28th, 2007